Sort   by:  
 Page size 
UnknownLonger Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
Not available
S-EPMC6286159 | biostudies-literature
UnknownVemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Not available
S-EPMC5834156 | biostudies-literature
UnknownSurrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.
Not available
S-EPMC4443445 | biostudies-literature
UnknownA randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma.
Not available
S-EPMC6279094 | biostudies-literature
UnknownSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Not available
S-EPMC4382632 | biostudies-literature
UnknownProlonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Not available
S-EPMC5648545 | biostudies-literature
UnknownFuture perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
Not available
S-EPMC3390271 | biostudies-literature
UnknownMelanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Not available
S-EPMC7851118 | biostudies-literature
UnknownCutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Not available
S-EPMC7618628 | biostudies-literature
UnknownComputational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research.
Not available
S-EPMC7665365 | biostudies-literature
Sort   by:  
 Page size